Development of antiangiogenic chemotherapy regimens

Hiroto Takahashi, Takashi Kondo

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Research in tumor angiogenesis is making rapid progress. It was recently confirmed that tumors utilize both vasculogenesis and existing blood vessels for angiogenesis, and angiogenesis has become a molecular target of new cancer therapies. Numerous inhibitors of angiogenesis have been developed and clinical trials conducted. However, problems such as side effects and the appropriate design of clinical trials have been noted, and the development of some inhibitors has stalled. Therefore more time and study will be required before clinical application of angiogenesis inhibitors is feasible. Trials combining existing chemotherapeutic regimens with angiogenesis inhibitors is feasible. Trials combining existing chemotherapeutic regimens with angiogenesis inhibitors, i.e., antiangiogenic chemotherapy, are underway in which low-dose anticancer and antiangiogenic agents are administered daily over the long term, and the results are awaited.

Original languageEnglish
Pages (from-to)237-243
Number of pages7
JournalNippon Geka Gakkai zasshi
Volume103
Issue number2
Publication statusPublished - 2002 Feb

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Development of antiangiogenic chemotherapy regimens'. Together they form a unique fingerprint.

  • Cite this

    Takahashi, H., & Kondo, T. (2002). Development of antiangiogenic chemotherapy regimens. Nippon Geka Gakkai zasshi, 103(2), 237-243.